G6PD Emerges as a Novel Therapeutic Resistance Marker in Kidney Cancer Treatment
High levels of G6PD in kidney cancer patients correlate with treatment resistance, particularly against VEGF inhibitors and immunotherapies. Research indicates that G6PD inhibitors may offer efficacy against Renal Cell Carcinoma (RCC) in cases unresponsive to conventional treatments, suggesting a promising new therapeutic approach despite being in early stages. Future clinical trials are anticipated.
Renal cell carcinoma (RCC), the prevalent form of kidney cancer with rising global incidence, continues to challenge treatment efficacy despite advancements in VEGF-targeted tyrosine kinase inhibitors (TKIs) and immunotherapy. Persistent therapeutic resistance underscores the critical need for additional biomarkers indicative of tumor aggressiveness and novel therapeutic targets. This study investigates the role of glucose-6-phosphate dehydrogenase (G6PD), where altered expression has been implicated in various cancers, as a potential biomarker and therapeutic target in RCC management.
Potential breakthrough biomarker for overcoming resistance in RCC treatment